OneSource Specialty Pharma Ltd
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]
- Market Cap ₹ 21,650 Cr.
- Current Price ₹ 1,891
- High / Low ₹ 2,250 / 1,163
- Stock P/E 242
- Book Value ₹ 514
- Dividend Yield 0.00 %
- ROCE 5.39 %
- ROE 2.60 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 3.68 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -4.46%
- Company has a low return on equity of -18.2% over last 3 years.
- Promoters have pledged or encumbered 25.0% of their holding.
- Debtor days have increased from 86.2 to 105 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 21 | 128 | 39 | 172 | 1,445 | 1,480 | |
| 93 | 132 | 199 | 254 | 978 | 990 | |
| Operating Profit | -71 | -4 | -161 | -82 | 467 | 490 |
| OPM % | -334% | -3% | -415% | -48% | 32% | 33% |
| 1 | -128 | -526 | -143 | -94 | -91 | |
| Interest | 16 | 46 | 48 | 89 | 166 | 152 |
| Depreciation | 34 | 53 | 66 | 76 | 274 | 273 |
| Profit before tax | -121 | -231 | -800 | -391 | -68 | -26 |
| Tax % | 0% | -0% | 0% | 0% | -73% | |
| -121 | -231 | -800 | -391 | -18 | -13 | |
| EPS in Rs | -1.57 | |||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 124% |
| TTM: | 225% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 150% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -18% |
| Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 11 |
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 |
| 386 | 1,182 | 864 | 571 | 942 | |
| 96 | 248 | 365 | 459 | 727 | |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,550 |
| 633 | 1,231 | 1,361 | 863 | 6,276 | |
| CWIP | 431 | 490 | 334 | 188 | 60 |
| Investments | 0 | 0 | 4 | 20 | 16 |
| 195 | 722 | 314 | 356 | 1,199 | |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,550 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -118 | -416 | -163 | -107 | -68 | |
| -207 | -692 | -68 | 511 | -201 | |
| 381 | 1,162 | 118 | -391 | 412 | |
| Net Cash Flow | 56 | 54 | -112 | 13 | 143 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 38 | 67 | 36 | 117 | 105 |
| Inventory Days | 87 | 615 | 258 | 133 | |
| Days Payable | 762 | 420 | 163 | 147 | |
| Cash Conversion Cycle | -637 | 67 | 232 | 212 | 91 |
| Working Capital Days | -2,392 | -1,331 | -6,745 | -877 | -83 |
| ROCE % | -3% | -12% | -12% | 5% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 Aug - Of Newspaper publication of Financial Results for the Quarter ended June 30, 2025
-
General Update
5 Aug - NSE fined Onesource Pharma Rs.77,880 for SEBI listing non-compliance; payment due in 15 days to avoid penalties.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
5 Aug - Audio recording of Q1 FY26 earnings call available on company website.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
4 Aug - Q1FY26: 12% revenue growth, 37% EBITDA growth; plans to acquire two USFDA-approved Steriscience sites.
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
4 Aug - Company has allotted 59,195 Equity shares under ONESOURCE ESOP 2021 scheme to the eligible employees upon exercise of vested options.
Annual reports
No data available.
Concalls
-
Aug 2025TranscriptNotesPPT REC
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.